Please login to the form below

Not currently logged in

EC unveils €80bn R&D investment programme

Horizon 2020 scheme designed to tackle ‘innovation emergency’ welcomed by European Federation of Pharmaceutical Industries & Associations

The European Commission (EC) has launched an €80bn package of measures designed to boost research, innovation and competitiveness in the EU over the remainder of the decade.

The Horizon 2020 scheme represents a dramatic shake-up of the way R&D is managed at the EU level, with funding now governed for the first time under a single programme, and will also do away with much of the red tape that can hamper R&D, according to the Commission.

The programme will run from 2014 to 2020, and include a dedicated budget of €25bn for EU science with a 77 per cent increase in funding for the European Research Council to €13bn.

Another €18bn will go on strengthening industrial leadership, with the money earmarked for investment in technologies, providing greater access to capital and supporting small- and medium-sized enterprises (SMEs).

Finally, almost €32bn has been set aside to address "major concerns shared by all Europeans such as climate change, developing sustainable transport and mobility, making renewable energy more affordable, ensuring food safety and security, or coping with the challenge of an ageing population," according to the EC.

"I've said many times that we have an innovation emergency in Europe, and Horizon 2020 is our response to that emergency," commented Máire Geoghegan-Quinn, Commissioner for Research, Innovation and Science.

"We need a new vision for European research and innovation in a dramatically changed economic environment."

The news was welcomed by the European Federation of Pharmaceutical Industries & Associations (EFPIA), which said it was pleased by the emphasis placed on public private partnerships in the Horizon 2020 document.

Richard Bergström, director general of EFPIA, pointed to the success of schemes such as the Innovative Medicines Initiative, which has been funded with €1bn apiece from the Commission and industry and promotes collaboration between pharma companies, academia and SMEs.

"EFPIA confirms industry interest in continuing public private collaborations which will enable game changing biopharmaceutical research projects that address scientific and technological bottlenecks in areas with grand societal challenges, such as antimicrobial resistance," he said.

Horizon 2020 will now be discussed by the European Parliament and by EU Member States.

1st December 2011


Subscribe to our email news alerts

Featured jobs


Add my company
Mednet Group

PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...

Latest intelligence

Virtual MSL/Sales training programs and events
Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
Omnichannel strategies to revolutionize the healthcare professional experience
Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...